

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4382084

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PHILIPPE DUCHATEAU	04/18/2017
ALEXANDRE JUILLERAT	04/12/2017
LAURENT POIROT	04/18/2017
RECEIVING PARTY DATA	
Name:	CELLECTIS
Street Address:	8 RUE DE LA CROIX JARRY
City:	PARIS
State/Country:	FRANCE
Postal Code:	F-75013
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15517708
CORRESPONDENCE DATA	
Fax Number:	(202)857-6395
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2028576000
Email:	patentdocket@arentfox.com
Correspondent Name:	ARENT FOX LLP
Address Line 1:	1717 K STREET, NW
Address Line 4:	WASHINGTON, D.C. 20006
ATTORNEY DOCKET NUMBER:	037328.00018
NAME OF SUBMITTER:	NATASHA BROWN
SIGNATURE:	/Natasha Brown/
DATE SIGNED:	04/24/2017
Total Attachments: 2	
source=037328.00018_ExecutedAssignment#page1.tif	
source=037328.00018_ExecutedAssignment#page2.tif	

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76) AND ASSIGNMENT

Title of Invention METHOD FOR MODULATING CAR-INDUCED IMMUNE CELLS ACTIVITY

As the below named inventor, I declare that:

This declaration

is directed to:

The attached application, or

United States application or PCT international application number 15/517,708
 filed on April 07, 2017

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I have reviewed and understand the contents of the above-identified application, including the claims.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.


For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, as assignor, hereby sell, assign and set over to CELLECTIS, having an address at 8 Rue de la Croix Jarry, F-75013, Paris, France, as assignee, the entire right, title and interest for the United States and all other countries in and to all inventions disclosed and/or claimed in the above-identified application, all original, divisional, continuation, substitute or reissue applications and patents applied for or granted therefor in the United States and all other countries, including all rights of priority from the filing of said application, and all rights for past infringement, and the Commissioner of Patents and Trademarks is hereby authorized and requested to issue a patent on said inventions or resulting there from to said assignee herein, as assignee of the entire interest therein; and the undersigned for myself and my legal representatives, heirs and assigns do hereby agree and covenant without further remuneration, to execute and deliver all divisional, continuation, reissue and other applications for Patent on said inventions and all assignments thereof to said assignee or its assigns, to communicate to said assignee or its representatives all facts known to the undersigned respecting said inventions, whenever requested, to testify in any interferences or other legal proceedings in which any of said applications or patents may become involved, to sign all lawful papers, make all rightful oaths, and to do generally everything necessary to assist assignee, its successors, assigns and nominees to obtain patent protection for said inventions in the United States and all other countries, the expenses incident to said applications to be borne and paid by said assignee.

The undersigned hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both, and may jeopardize the validity of the application or any patent issuing thereon.


LEGAL NAME OF INVENTOR


Inventor: Philippe DUCHATEAU Date: April 18, 2017

**Signature: 

LEGAL NAME OF INVENTOR

Inventor: Alexandre JUILLERAT Date: 04/12/2017

**Signature: 

LEGAL NAME OF INVENTOR	
Inventor: <u>Laurent POIZOT</u>	Date: <u>April 18, 2017</u>
**Signature: <u></u>	

** An electronic S-signature is permitted. The S-signature must consist only of letters, or Arabic numerals, or both, with appropriate spaces and commas, periods, apostrophes, or hyphens for punctuation, and the person signing the correspondence must insert his or her text S-signature with a first single forward slash mark before and a second single forward slash mark after the S-signature. (e.g., /Dr. James T. Jones, Jr./).